

24.12.2020

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building,
Phiroze jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.
Scrip Code: 524742

By BSE Listing

National Stock Exchange of India Ltd.,
Department of Corporate Services,
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.
Scrip Code: CAPLIPOINT

By NEAPS

Dear Sirs,

SUB:PRESS RELEASE–DISCLOSURE UNDER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

Please find the enclosed copy of Press Release being published today.

Thanking You,

Yours Faithfully,
For Caplin Point Laboratories Limited


Company Secretary
Enclosure: As above



PRESS RELEASE

CAPLIN STERILES GETS USFDA APPROVAL FOR ETOMIDATE INJECTION USP

Chennai, December 24, 2020: Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT) Caplin Steriles Limited, a Subsidiary Company of Caplin Point Laboratories Limited, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Etomidate injection USP, 20 mg/10 mL (2 mg/mL) and 40 mg/20 mL (2 mg/mL) Single-dose vial presentations, a generic therapeutic equivalent version of (RLD), AMIDATE (Etomidate) Injection, of HOSPIRA INC. According to IQVIA™ (IMS Health), Etomidate injection USP had US sales data of approximately \$9 million for the 12-month period ending Oct 2020. Caplin Steriles Limited, has developed and filed 19 ANDAs on its own and with partners, with 11 approvals so far.

Etomidate is a general anesthetic, used for the induction of general anesthesia and for the supplementation of subpotent anesthetic agents.

Mr.C.C.Parthipan, Chairman of Caplin Point Laboratories Limited commented “We understand Etomidate injection has frequently been on the shortage list in the US, which is probably the reason why we received this approval within 6 months. We hope to launch this product within a short period in the US”

The Company is also working on a portfolio of 35 simple and complex Injectable and Ophthalmic products, to be filed over the next 4 years, with an addressable market size of USD 2.1 Billion

ABOUT CAPLIN POINT LABORATORIES LIMITED:

Caplin Point Laboratories Limited is a fast-growing pharmaceutical Company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company’s Subsidiary Caplin Steriles Limited caters to the Regulated Markets for Injectable and Ophthalmic products.

Caplin Point Laboratories Limited has been selected on Forbes Asia’s “200 Best Under a Billion” list for three consecutive years (2014, 2015 & 2016), and was recently awarded “The Emerging Company of 2018” and “Business Excellence Award for 2019” by Economic Times.





Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and Caplin Point has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

Investor Relations at Caplin

Mr. Vinod Kumar (Company Secretary)

Tel: +91 44 24968000

investor@caplinpoint.net

Mr. Rahul Thakur

Ernst & Young LLP,

Rahul.thakur@in.ey.com

Registered Office

3rd Floor, Ashvich Towers,

No. 3, Developed Plots Industrial
Estate, Perungudi,

Chennai – 600 096, Tamil Nadu, INDIA.

Tel : +91 44 2496 8000

CIN: L24231TN1990PLC019053

ISIN: INE475E01026

NSE Code: CAPLIPOINT

BSE CODE: 524742

Website: www.caplinpoint.net

